Molecular mysteries of polycystic ovary syndrome

Molecular Endocrinology

Volumn 13, Issue 6, 1999, Pages 800-805

  Strauss III, Jerome F ^a,c   Dunaif, Andrea ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c 778 Clinical Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LUTEINIZING HORMONE;

FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HORMONE SYNTHESIS; HUMAN; INSULIN RESISTANCE; MOLECULAR BIOLOGY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; STEROIDOGENESIS;

EID: 0033304707     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.13.6.0285     Document Type: Short Survey

References (47)

1. Phenotype and genotype in polycystic ovary syndrome
2. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southestern United States: A prospective study
3. Insulin resistance and polycystic ovary syndrome: Mechanisms and implications for pathogenesis
4. Defects in beta-cell function in functional hyperandrogenism
5. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
6. Insulin resistance and preeclampsia
7. Amenorrhea associated with bilateral polycystic ovaries
8. Suppression of serum insulin by diaxoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
9. Decreases in ovarian cytochrome P450c 17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
10. The insulin-sensitizing agent troglitazone improves reproductive abnormalities in the polycystic ovary syndrome
11. Troglita zone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
12. Effects of metformin on spontaneous and clomiphene induced ovulation in the polycystic ovary syndrome
13. Troglitazone inhibits progesterone production in porcine granulosa cells
14. Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome
15. Clinical features of primary ovarian failure caused by a point mutation in the follicle stimulating hormone receptor gene
16. Activating and inactivating mutations in LH receptors
17. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome
18. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing-hormone agonist challenge in functional ovarian hyperandrogenism
19. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: Implications for adrenarche and polycystic ovary syndrome
20. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries
21. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries
22. The role of intraovarian regulators in the aetiology of polycystic ovarian syndrome
23. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: Relevance to mechanism of anovulation
24. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism
25. Mechanism of insulin-like growrh factor I augmentation of follicle-stimulating hormone-induced porcine steroidogenic acute regulatory protein gene promoter activity in granulosa cells
26. Concerted regulation of low density lipoprotein receptor gene expression by follicle-stimulating hormone and insulin-like growth factor I in porcine granulosa cells: Promoter activation, messenger ribonucleic acid stability, and sterol feedback
27. Detection of an alteration in the insulin receptor gene in a patient with insulin resistance, acanthosis nigricans and the polycystic ovary syndrome
28. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-l insulin-like growth factor receptor
29. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries
30. Mutation of the two carboxyl-terminal tyrosines results in an insulin receptor with normal metabolic signalling but enhanced mitogenic signaling properties
31. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance
32. Wortmannin inhibits the action of insulin but not that of okadaic acid in skeletal muscle. Comparison with fat cells
33. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system
34. Absence of insulin receptor gene mutations in three women with polycystic ovary syndrome
35. Molecular scanning of the insulin receptor gene in women with polycystic ovary syndrome
36. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle
37. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity
38. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome
39. Polycystic ovaries are inherited as an autosomal dominant trait: Analysis of 29 polycystic ovary syndrome and 10 control families
40. The genetic basis of polycystic ovary syndrome
41. The 17α-hydroxylase/17,20 lyase (CYP17) and polycystic ovary syndrome
42. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism
43. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome
44. Genetic analysis of candidate genes for polycystic ovary syndrome (PCOS)
45. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome